Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal cancer-a Prospective, Open, Single Center and Randomized Controlled Phase Ⅱ Clinical Trial
Latest Information Update: 29 Sep 2021
Price :
$35 *
At a glance
- Drugs Capecitabine (Primary) ; Catequentinib (Primary) ; Oxaliplatin (Primary)
- Indications Adenocarcinoma; Rectal cancer
- Focus Therapeutic Use
- 22 Sep 2021 Planned End Date changed from 1 Oct 2024 to 1 Dec 2023.
- 22 Sep 2021 Planned primary completion date changed from 1 Oct 2021 to 1 Nov 2023.
- 22 Sep 2021 Status changed from not yet recruiting to withdrawn prior to enrolment.